Short answer
Viridian Therapeutics, Inc.\DE (VRDN) filed an 8-K current report with the SEC on May 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Item 2.02 contains only a filing-status disclaimer, not operating results or financial figures.
Viridian Therapeutics, Inc.\DE 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 contains only a filing-status disclaimer, not operating results or financial figures
- No earnings period, revenue, profitability, guidance, or other investor-actionable information provided
Item EX-99.1 · Exhibit EX-99.1
- Q1 2026 net loss $104.9M, or $0.90 per common share, versus $86.9M and $0.87 in Q1 2025
- Cash, cash equivalents, and marketable securities $762.2M at March 31, 2026, down from $874.7M at year-end
- Veligrotug FDA PDUFA target June 30, 2026, with commercial infrastructure and field teams ready for potential launch
- Elegrobart phase 3 proptosis response rates reached 54%-63% in active TED and 50%-54% in chronic TED versus 15%-18% placebo
- BLA submission for subcutaneous elegrobart planned for Q1 2027, targeting Q4W and Q8W autoinjector dosing regimens
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Viridian Therapeutics, Inc.\DE 8-K filings
Get the next VRDN 8-K as it lands
Follow VRDN for push alerts, or ask the research agent what this filing means.